Skip to main content
Equibles
JRSS logo

JRSS · JRSIS HEALTH CARE Corp · Metrics

Track JRSS — free

Use JRSS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JRSS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.01 At close · Oct 15
Rebalance outlook locked
Going-concern doubt — flagged Dec 20, 2024

Substantial doubt about the company's ability to continue as a going concern.

“Management believes these factors raise substantial doubt about the Company's ability to continue as a going concern for the next twelve months. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Dec 20, 2024
Market Cap
$1.10M
Shares
84.60M
Volume · Oct 15 2575 Avg daily vol (8 sessions) 3648

JRSS metrics

57 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.01
Market cap
$1.10M

Price action

23 metrics
Price change (1W)
-7.1%
Price change (30D)
-7.1%
Price change (3M)
-16.7%
Price change (6M)
—
Price change (YTD)
-28.2%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$0.13
52-week low
$0.01
Change from 52-week high
-90.0%
Change from 52-week low
+80.6%
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
43.9
Price vs SMA 50
-51.8%
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Consumer Cyclical
Industry
Specialty Retail
Shares outstanding
84.60M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.3×
reciprocal yield 307.2%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 315.6%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-45.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
12.7%
Operating margin
-19.5%
Trailing 12 months
Net margin
-14.5%
Gross profit (TTM)
$442,158
Operating profit (TTM)
−$675,664
Net income (TTM)
−$503,656
Trailing 12 months
Diluted EPS (TTM)
$-0.01
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.04
Gross profit per diluted share (TTM)
$0.01
Operating profit per diluted share (TTM)
$-0.01
EBITDA per diluted share (TTM)
$-0.01
Net income per diluted share (TTM)
$-0.01
Operating cash flow per diluted share (TTM)
$-0.01
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.00
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
-55.2%
Year over year
Net income growth YoY
-658.2%
Revenue (TTM)
$3.47M
Trailing 12 months
EPS growth YoY
-650.0%
Shares change YoY
+10.2%
Year over year · more shares
Revenue CAGR (3Y)
-54.1%
Revenue CAGR (5Y)
-34.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
-39.9%
FCF CAGR (5Y)
-38.6%

Quality

14 metrics
Return on equity
—
Return on assets
-24.3%
Debt / equity
—
Current ratio
0.8
EBITDA (TTM)
−$604,101
Free cash flow (TTM)
—
Quick ratio
0.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$30,182
Latest balance sheet
Cash & equivalents
$1,372
Total assets
$2.07M
Total debt
$31,554

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$730,303
Capital expenditures (TTM)
$233,701
R&D (TTM)
$133,118
SG&A (TTM)
—
Stock compensation (TTM)
$327,287
R&D / revenue
3.8%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1597892